Tomonari Koike
Overview
Explore the profile of Tomonari Koike including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koike T, Koike Y, Niimi M, Guo Y, Yang D, Song J, et al.
Arterioscler Thromb Vasc Biol
. 2025 Mar;
PMID: 40047072
No abstract available.
2.
Wang D, Yu B, Li Q, Guo Y, Koike T, Koike Y, et al.
J Mol Cell Biol
. 2022 Mar;
14(3).
PMID: 35278086
Lipoprotein, especially high-density lipoprotein (HDL), particles are composed of multiple heterogeneous subgroups containing various proteins and lipids. The molecular distribution among these subgroups is closely related to cardiovascular disease (CVD)....
3.
Song J, Hoenerhoff M, Yang D, Yang Y, Deng C, Wen L, et al.
Stem Cell Reports
. 2021 Feb;
16(3):656-665.
PMID: 33606990
Loss-of-function mutations in the forkhead box N1 (FOXN1) gene lead to nude severe combined immunodeficiency, a rare inherited syndrome characterized by athymia, severe T cell immunodeficiency, congenital alopecia, and nail...
4.
Koike T, Koike Y, Yang D, Guo Y, Rom O, Song J, et al.
Atherosclerosis
. 2020 Dec;
316:32-40.
PMID: 33296791
Background And Aims: Apolipoprotein A-II (apoAII) is the second major apolipoprotein of the high-density lipoprotein (HDL) particle, after apoAI. Unlike apoAI, the biological and physiological functions of apoAII are unclear....
5.
Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, et al.
Sci Transl Med
. 2020 Dec;
12(572).
PMID: 33268508
Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) has reached epidemic proportions with no pharmacological therapy approved. Lower circulating glycine is consistently reported in patients with NAFLD, but the...
6.
Chen Y, Waqar A, Nishijima K, Ning B, Kitajima S, Matsuhisa F, et al.
J Cell Mol Med
. 2020 Mar;
24(7):4261-4274.
PMID: 32126159
Matrix metalloproteinase-9 (MMP-9), or gelatinase B, has been hypothesized to be involved in the progression of atherosclerosis. In the arterial wall, accumulated macrophages secrete considerable amounts of MMP-9 but its...
7.
Takeda H, Izumi Y, Tamura S, Koike T, Koike Y, Shiomi M, et al.
J Proteome Res
. 2020 Jan;
19(3):1100-1108.
PMID: 31965805
Statins are widely used for the treatment of atherosclerotic cardiovascular diseases. They inhibit cholesterol biosynthesis in the liver and cause pleiotropic effects, including anti-inflammatory and antioxidant effects. To develop novel...
8.
Shiomi M, Takeda H, Irino Y, Kimura N, Yamada S, Kuniyoshi N, et al.
Atherosclerosis
. 2019 Mar;
284:18-23.
PMID: 30870703
Background And Aims: The development of serum markers specific for coronary lesions is important to prevent coronary events. However, analyses of serum markers in humans are affected by environmental factors...
9.
Takeda H, Izumi Y, Takahashi M, Paxton T, Tamura S, Koike T, et al.
J Lipid Res
. 2018 May;
59(7):1283-1293.
PMID: 29724780
Lipidomics, the mass spectrometry-based comprehensive analysis of lipids, has attracted attention as an analytical approach to provide novel insight into lipid metabolism and to search for biomarkers. However, an ideal...
10.
Tamura S, Koike Y, Takeda H, Koike T, Izumi Y, Nagasaka R, et al.
Eur J Pharmacol
. 2018 Jan;
822:147-153.
PMID: 29355561
Improvements induced in lipid metabolism in the liver by D-47, a newly developed compound, were examined herein. WHHLMI rabbits, an animal model of hypercholesterolemia and coronary atherosclerosis, was fed D-47-supplemented...